DOI: 10.1182/blood.2023021212 ISSN:
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
Aldo A. Acosta-Medina, Paul Geraeds Kemps, Timo CE Zondag, Jithma P. Abeykoon, Jelske Forma-Borst, Eline Christine Steenwijk, Elizabeth A.M. Feijen, Jop C. Teepen, N. Nora Bennani, Susan M. Schram, Mithun Vinod Shah, Caroline Davidge-Pitts, Matthew J. Koster, Jay Ryu, Robert Vassallo, W. Oliver Tobin, Jason R. Young, Surendra Dasari, Karen L. Rech, Aishwarya Ravindran, Arjen HG Cleven, Robert M. Verdijk, Carel J.M. van Noesel, Brian V. Balgobind, Gerrit J. Bouma, Peerooz Saeed, Jos A.M. Bramer, Ruben AL de Groen, Joost S.P. Vermaat, Michiel A.J. van de Sande, Egbert F. Smit, Anton W. Langerak, Tom van Wezel, Sanne H. Tonino, Cor van den Bos, Jan AM van Laar, Ronald S. Go, Gaurav Goyal, Astrid G.S. van Halteren- Cell Biology
- Hematology
- Immunology
- Biochemistry
In this retrospective study, BRAFmutation status did not correlate with disease extent or (event-free) survival in 156 adults with LCH. BRAFV600E was associated with an increased incidence of second malignancies, often comprising hematological cancers - which may be clonally related.